None listed
Conditions
Interventions
Drug : During maintenance of anesthesia with sevoflurane and remifentanil after induction, patients in the nefopam group receive 20 mg of nefopam diluted in 100 ml of normal saline infused at 400 ml/h
Sponsors
Yeongnam University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Undergoing transurethral resection of bladder tumor 2) American Society of Anesthesiologists (ASA) physical status classification I and II
Exclusion criteria
Exclusion criteria: i) Patients with known allergy to the study drugs ii) Patients with urinary retention or overactive bladder (voiding more than 3 times per night or more than 8 times per 24 hours) iii) Patients with a history of epilepsy, seizure, myocardial infarction, arrhythmia, heart failure, renal or hepatic disease, or current use of monoamine oxidase (MAO) inhibitors iv) Patients with angle-closure glaucoma v) Patients with a history of drug or alcohol abuse vi) Patients receiving opioid or sedative therapy vii) Patients with hypersensitivity to the anesthetic agents used in the study viii) Patients with morbid obesity (body mass index > 30 kg/m²) ix) Pregnant or breastfeeding women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and severity of postoperative catheter-related bladder discomfort ? | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative pain scores and demand for analgesics;Presence of PONV, cold sweats, xerostomia, shivering, dizziness, sedation, headache, and visual blurring postoperatively;Quality of recovery, using QoR 15 | — |
Countries
Korea, Republic of
Contacts
Public Contactchoe eun kyung
Yeongnam University Medical Center
Outcome results
None listed